Veracyte is a leading molecular diagnostics company based in Austin, TX, specializing in providing exceptional cancer care through their high-value insights and tests. Their comprehensive portfolio includes genomic sequencing classifiers for diseases such as thyroid cancer, prostate cancer, lung cancer, breast cancer, bladder cancer, and interstitial lung disease, among others. Veracyte's tests enable clinicians and patients to make more informed and confident decisions, avoiding unnecessary procedures and speeding up the time to appropriate diagnosis and treatment.
With a proven framework and a collaborative approach with clinicians and scientists, Veracyte identifies unmet needs in cancer care and develops high-performance tests to address them. Their rigorous process ensures product performance and utility, building evidence through a broad range of studies. Veracyte aims to make leading diagnostics accessible to patients worldwide, with their centralized CLIA lab-based approach in the US and a growing menu of distributed in vitro diagnostic (IVD) tests to serve global markets.
Generated from the website